Flow cytometric characterization and clinical outcome of CD4+ T-cell lymphoma in dogs: 67 cases.
BACKGROUND
Canine T-cell lymphoma (TCL) is conventionally considered an aggressive disease, but some forms are histologically and clinically indolent. CD4 TCL is reported to be the most common subtype of TCL. We assessed flow cytometric characteristics, histologic features when available, and clinical outcomes of CD4+ TCL to determine if flow cytometry can be used to subclassify this group of lymphomas.


OBJECTIVE
To test the hypothesis that canine CD4+ T-cell lymphoma (TCL) is a homogeneous group of lymphomas with an aggressive clinical course.


METHODS
Sixty-seven dogs diagnosed with CD4+ TCL by flow cytometry and treated at 1 of 3 oncology referral clinics.


METHODS
Retrospective multivariable analysis of outcome in canine CD4+ TCL including patient characteristics, treatment, and flow cytometric features.


RESULTS
The majority of CD4+ TCL were CD45+, expressed low class II MHC, and exhibited an aggressive clinical course independent of treatment regimen (median survival, 159 days). Histologically, CD4+ TCL were classified as lymphoblastic or peripheral T cell. Size of the neoplastic lymphocytes had a modest effect on both PFI and survival in this group. A small number of CD4+ TCL were CD45- and class II MHC high, and exhibited an apparently more indolent clinical course (median survival not yet reached).


CONCLUSIONS
Although the majority of CD4+ TCL in dogs had uniform clinical and flow cytometric features and an aggressive clinical course, a subset had a unique immunophenotype that predicts significantly longer survival. This finding strengthens the utility of flow cytometry to aid in the stratification of canine lymphoma.
Department of Microbiology, Immunology and Pathology, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO; Flint Animal Cancer Center, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO.
P R
PR
Avery
J
J
Burton
J L
JL
Bromberek
D M
DM
Seelig
R
R
Elmslie
S
S
Correa
E J
EJ
Ehrhart
P S
PS
Morley
A C
AC
Avery
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D018791:CD4 Lymphocyte Count / Q000662:veterinary*; D015496:CD4-Positive T-Lymphocytes / Q000473:pathology; D004283:Dog Diseases / Q000097:blood* / Q000175:diagnosis / Q000188:drug therapy / Q000473:pathology; D004285:Dogs; D005260:Female; D005434:Flow Cytometry / Q000662:veterinary; D016399:Lymphoma, T-Cell / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy / Q000473:pathology / Q000662:veterinary*; D008297:Male; D012189:Retrospective Studies; D016896:Treatment Outcome
D000970:Antineoplastic Agents
Canine; Immunophenotyping; Lymphoblastic; Peripheral T cell; Prognosis